PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS

A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2and R3are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically accept...

Full description

Saved in:
Bibliographic Details
Main Authors LYSSIKATOS, JOSEPH P, HURLEY, CHRISTOPHER, HANAN, EMILY, ZAK, MARK E, GIBBONS, PAUL, RAWSON, THOMAS E, ZHOU, AIHE, LIU, WENDY, MAGNUSON, STEVEN R, PASTOR, RICHARD, ZHU, BING-YAN, MENDONCA, ROHAN, SIU, MICHAEL
Format Patent
LanguageEnglish
Polish
Published 30.05.2018
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2and R3are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
Bibliography:Application Number: PL20100794815T